AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in …

Oct 28, 2024 · "Neuroscience is one of our key growth areas and we are committed to driving innovation in this field to address critical unmet needs for patients living with seriously …

CouponFollow Extension

$1
OFF

AbbVie Inks $1.4B Aliada Buyout To Land Ex-J&J Alzheimer's Drug

1 week from now

Oct 28, 2024 · AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The acquisition will give AbbVie control of an Alzheimer’s disease drug candidate Aliada in-licensed from …

fiercebiotech.com

$1
OFF

AbbVie To Acquire Aliada Therapeutics For $1.4 Billion, Expanding ...

1 week from now

Oct 29, 2024 · The terms of the agreement specify that AbbVie will purchase all existing shares in Aliada for $1.4 billion. Assuming regulatory clearance, the transaction is projected to conclude …

yahoo.com

$1
OFF

AbbVie Banks On Alzheimer's Therapy With $1.4 Billion Buy Of Aliada

1 week from now

Oct 28 (Reuters) - U.S. drugmaker AbbVie , opens new tab said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental Alzheimer's treatment still in …

reuters.com

$1
OFF

AbbVie Acquires Aliada Therapeutics In $1.4bn Deal

1 week from now

Oct 30, 2024 · AbbVie and Aliada Therapeutics have inked an acquisition deal under which AbbVie will acquire all outstanding equity of Aliada for a total of $1.4 billion. Following the …

biopharma-reporter.com

$1
OFF

AbbVie To Acquire Aliada Therapeutics For $1.4 Billion

1 week from now

Oct 28, 2024 · AbbVie has agreed to buy Aliada Therapeutics, a biotechnology company backed by Johnson & Johnson, for $1.4 billion in cash in a deal that adds a potential therapy for …

wsj.com

$1
OFF

AbbVie's Bold $1.4 Billion Bet: The Alzheimer's Breakthrough …

1 week from now

Oct 28, 2024 · AbbVie's $1.4 billion acquisition of Aliada Therapeutics is more than a routine buyit's a strategic leap into high-stakes Alzheimer's innovation. Aliada's ALIA-1758, an …

yahoo.com

$8
OFF

AbbVie Axes Alzheimer's Program Amid 'evolving Landscape'

1 week from now

Jul 25, 2024 · While AbbVie has abandoned this Alzheimer’s program, the pharma still has a heavy hand in neuroscience, with the $8.7 billion acquisition of Cerevel Therapeutics expected …

fiercebiotech.com

$225
OFF

AbbVie Partners With Alector In $225 Million Alzheimer's Disease …

1 week from now

Biotech startup Alector just got a $225 million endorsement from pharma giant AbbVie for its work in neurodegenerative diseases. Alector's developing treatments that harness the body's …

businessinsider.com

FAQs about AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in … Coupon?

Will AbbVie buy aliada Therapeutics?

AbbVie (ABBV, Financials) announced it will acquire biotechnology company Aliada Therapeutics in a $1.4 billion all-cash transaction. By including Aliada's new blood-brain barrier-crossing technology and lead chemical ALIA-1758, the purchase will strengthen AbbVie's neuroscience portfoliomore especially, its emphasis on Alzheimer's disease. ...

Where can I find more information about AbbVie?

For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. About Aliada Therapeutics Aliada Therapeutics is a biotechnology company focused on addressing delivery challenges in CNS drug development. ...

Why is neuroscience a key growth area at AbbVie?

"Neuroscience is one of our key growth areas and we are committed to driving innovation in this field to address critical unmet needs for patients living with seriously debilitating neurological diseases such as Alzheimer's disease," said Roopal Thakkar, M.D., executive vice president, research and development and chief scientific officer, AbbVie. ...

How many warning signs are there with abbv?

GuruFocus has detected 9 Warning Signs with ABBV. AbbVie is doubling down on neuroscience, a smart pivot as Humira sales dip amid biosimilar competition. Aliada's MODEL platform solves a critical challenge: crossing the BBB, which has stalled many CNS treatments in late-stage trials. ...

Why did AbbVie shares close 1% on Monday?

AbbVie shares closed up 1% on Monday. Competition for privately held Aliada's Alzheimer's candidate drove up the deal price, the person said, a sign of willingness to invest early in such treatments despite the history of regulatory risk for drugs for the mind-wasting disease. ...

Who was AbbVie's legal advisor?

AbbVie's legal advisor was Covington & Burling LLP. Aliada's exclusive financial advisor was Centerview Partners LLC and Fenwick & West LLP served as legal advisor. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. ...